Clinigen Group PLC represents a strong set of values and corporate philosophy. The company is driven by a commitment to improving the lives of patients and providing access to critical medicines. Clinigen embraces a patient-centric approach, ensuring that their products and services address unmet medical needs. With a focus on quality, integrity, and innovation, Clinigen strives to deliver exceptional healthcare solutions globally. The company's dedication to collaborating with stakeholders, including healthcare professionals and regulatory bodies, contributes to their success and ongoing growth. Clinigen Group PLC continues to make a significant impact in the pharmaceutical industry through its commitment to excellence and patient care.

Clinigen Group PLC is primarily present in multiple countries and regions worldwide. The company has a global presence with a strong focus on Europe, North America, and Asia Pacific. Clinigen operates in numerous key markets, including the United Kingdom, United States, Germany, France, Spain, Italy, Japan, and Australia, among others. This widespread geographic reach allows Clinigen to offer its pharmaceuticals and services to a diverse customer base across different markets, ensuring access to vital medicines and clinical trial services. As a leading global specialty pharmaceutical and services company, Clinigen Group PLC continues to expand its presence and serve patients and healthcare professionals in numerous countries and regions seamlessly.

Clinigen Group PLC has achieved several significant milestones throughout its history. The company has successfully expanded its global footprint, establishing a strong presence in key markets around the world. Clinigen has consistently demonstrated its commitment to innovation by developing and launching various innovative products and solutions. The company has also entered into strategic partnerships and collaborations, further enhancing its capabilities and reach. Additionally, Clinigen has received numerous accolades and awards for its outstanding performance and contribution to the healthcare industry. These milestones highlight Clinigen Group PLC's remarkable growth and success in delivering valuable healthcare solutions globally.

Clinigen Group PLC is a leading global pharmaceutical and services company. Established in 2010, Clinigen has a rich history of providing access to medicines and clinical trial services. With its headquarters in the United Kingdom, the company has expanded its operations across the globe, serving patients, healthcare professionals, and pharmaceutical companies. Clinigen specializes in providing access to unlicensed and licensed medicines, managing clinical trials, and offering data and insights to facilitate informed decision making in healthcare. With a commitment to improving the quality of life for patients worldwide, Clinigen Group PLC continues to grow and innovate in the pharmaceutical industry.

The main competitors of Clinigen Group PLC in the market are: Catalent Inc., AmerisourceBergen Corporation, and McKesson Corporation.

Clinigen Group PLC is primarily active in the healthcare and pharmaceutical industries. With a focus on providing specialist clinical trial supply, unlicensed medicines, and managed access programs, Clinigen plays a vital role in ensuring patients have access to the medications they need. The company is committed to improving outcomes for patients worldwide, particularly in areas of high unmet need. Through strategic partnerships and collaborations, Clinigen continues to expand its reach and impact in the healthcare industry.

The business model of Clinigen Group PLC focuses on providing global access to ethical, regulated, and rare pharmaceutical products. The company operates in three key areas: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. Clinigen works closely with pharmaceutical companies to distribute their products to patients in need, especially those with rare or life-threatening conditions. Through its global infrastructure and strong partnerships, Clinigen ensures efficient supply chain management, regulatory compliance, and ethical distribution practices. By bridging the gap between pharmaceutical manufacturers and patients, Clinigen Group PLC plays a vital role in improving healthcare outcomes worldwide.

Az Clinigen Group P/E mutatója 14,15.

Az Clinigen Group KUV 2,01.

Az AlleAktien Minőségi Score Clinigen Group esetében 6/10.

A várt Clinigen Group forgalma 624,40 Mió. GBP.

A(z) várt Clinigen Group nyereség 88,82 Mió. GBP.

The Clinigen Group PLC is a globally operating company specialized in the procurement, distribution, and delivery of pharmaceuticals, particularly specialty pharmaceuticals, as well as providing services related to pharmaceuticals. The Clinigen Group's business model encompasses three core areas: AGF (Access, Global Specialty Pharmaceuticals), CTS (Clinical Trial Services), and Idis Managed Access. The AGF division is divided into two main categories: specialty pharmaceuticals and clinically unused pharmaceuticals. Specialty pharmaceuticals include drugs for the treatment of rare or life-threatening diseases and require special distribution and logistics capabilities. The Clinigen Group offers a complete end-to-end solution, ranging from procurement to distribution and marketing activities, to logistics and supply to patients. The clinically unused pharmaceuticals division provides an opportunity to bring unused drugs from clinical trials to market or reintroduce them. The Clinigen Group has a pool of unused drugs and works closely with research organizations to facilitate access to these drugs. The Clinical Trial Services division (CTS) offers a comprehensive range of services to support clinical trials. This includes a variety of services, such as Interactive Response Technology (IRT), clinical supply management, and the manufacturing and logistics of Investigational Medicinal Products (IMP). The goal is to make clinical trials more efficient, effective, and cost-effective. Idis Managed Access is a distribution channel that enables patients, physicians, and companies to access unlicensed pharmaceuticals. The aim is to provide access to innovative therapies for patients with rare or life-threatening diseases who have no approved treatment options. The Clinigen Group's product range includes a wide variety of specialty pharmaceuticals, clinically unused pharmaceuticals, and access solutions. The company partners with a variety of pharmaceutical companies and research organizations to facilitate access to specialty pharmaceuticals and other therapies. The Clinigen Group pursues a differentiated business model focused on targeting new markets and providing solutions for complex healthcare needs. The company has a value-enhancing value chain that extends from pharmaceutical procurement to delivery to end consumers. With this model, the Clinigen Group is able to offer a wide range of products and services to global customers while ensuring compliance with regulatory standards. Only the answer should be written in the output.

A(z) Clinigen Group évente alkalommal oszt ki 0 GBP összegű osztalékot.

A Clinigen Group esetében jelenleg nem lehet kiszámítani a osztalékot, vagy a vállalat nem fizet osztalékot.

A(z) Clinigen Group ISIN kódja: GB00B89J2419.

Az Clinigen Group tőzsdei rövidítése CLIN.L.

Az elmúlt 12 hónapban a(z) Clinigen Group osztalékot fizetett 0,08 GBP összegben. Ez körülbelül 0,82 % osztalékhozamnak felel meg. A következő 12 hóban a(z) Clinigen Group várhatóan 0,54 GBP összegű osztalékot fog fizetni.

A(z) Clinigen Group jelenlegi osztalékhozama 0,82 %.

A(z) Clinigen Group negyedévente fizet osztalékot. Az osztalékokat a következő hónapokban osztják ki: április, december, április, január.

A Clinigen Group az elmúlt 14 évben minden évben fizetett osztalékot.

A következő 12 hónapban 0,54 GBP összegű osztalékra számítanak. Ez 5,87 % osztalékhozamnak felel meg.

A(z) Clinigen Group a(z) 'Egészség' szektorhoz van besorolva.

Az utolsó, Clinigen Group által 2022. 01. 04.-án/én fizetett 0,055 GBP összegű osztalék megszerzéséhez a részvénynek az ex-nap előtti 2021. 12. 02.-nál kellett lennie a portfóliódban.

Az utolsó osztalék kifizetése 2022. 01. 04. időpontban történt.

2023 évben a Clinigen Group 0,514 GBP összegű osztalékot fizetett ki.

Az Clinigen Group osztalékait GBP fizeti ki.